Journal of Clinical Virology
Volume 46, Issue 4 , Pages 305-308 , December 2009

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life

  • Philip M. Grant

      Affiliations

    • Stanford University, Palo Alto, CA 94305, USA
    • Corresponding Author InformationCorresponding author at: Stanford University, Division of Infectious Diseases; 300 Pasteur Drive, Rm. S-101; Stanford, CA 94305-5107, USA. Tel.: +1 650 354 8101; fax: +1 650 354 8102.
    • ,
  • Sarah Palmer

      Affiliations

    • Swedish Institute for Infectious Disease Control, Karolinska Institute, SE-171 77 Stockholm, Sweden
    • ,
  • Eran Bendavid

      Affiliations

    • Stanford University, Palo Alto, CA 94305, USA
    • ,
  • Annie Talbot

      Affiliations

    • Stanford University, Palo Alto, CA 94305, USA
    • ,
  • Debbie C. Slamowitz

      Affiliations

    • Stanford University, Palo Alto, CA 94305, USA
    • ,
  • Pat Cain

      Affiliations

    • Stanford University, Palo Alto, CA 94305, USA
    • ,
  • Stacy S. Kobayashi

      Affiliations

    • Stanford University, Palo Alto, CA 94305, USA
    • ,
  • Maya Balamane

      Affiliations

    • Stanford University, Palo Alto, CA 94305, USA
    • ,
  • Andrew R. Zolopa

      Affiliations

    • Stanford University, Palo Alto, CA 94305, USA

Received 20 July 2009 ,Revised 16 September 2009 ,Accepted 19 September 2009.

References 

  1. Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175–2186
  2. Lazzarrin A, Clotet B, Cooper D, Reyne J, Arasteh K, Nelson M, et al. Efficacy of Enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186–2195
  3. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796–806
  4. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–354
  5. Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS. 2008;22:1224–1226
  6. Talbot A, Machouf N, Thomas R, Marcotte S, Therrien R, Lessard B, et al. Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort. J Acquir Immune Defic Syndr. 2009;51:362–364
  7. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3:e46
  8. Center for AIDS Prevention Studies. Available at http://www.caps.ucsf.edu/tools/surveys/#8. Accessed August 21, 2007.
  9. Wu AW, Rubin HR, Mathews WC, Ware JE, Brysk LT, Hardy WD, et al. Health status questionnaire using 30 items from the Medical Outcomes Study: a preliminary validation in persons with early HIV infection. Med Care. 1991;29:786–798
  10. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for Human Immunodeficiency Virus Type 1 RNA in plasma. J Clin Microbiol. 2003;41:4531–4536
  11. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16:62–68
  12. Lafaurie M, Collin F, Bentata M, Garré M, Leport C, Levy Y, et al. Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial. J Antimicrob Chemother. 2008;62:1122–1129
  13. Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother. 2008;61:200–205
  14. Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44:1484–1492
  15. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–2106
  16. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429–1441
  17. Madruga JR, Cassetti I, Suleiman JM, Etzel A, Zhong L, Holmes CB, et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials. 2007;8:381–390
  18. Raboud JM, Montaner JSG, Conway B, Rae S, Reiss P, Vella S, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve long term suppression. AIDS. 1998;12:1619–1624
  19. Sayana S, Prosser P, Ricaurte JC, Sanchez S, Hamwi G, Hershey-Weber J, et al. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks. J Int Assoc Phys AIDS Care. 2009;8:85–86
  20. De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, et al. Switch from enfuvirtide to raltegravir in highly treatment-experienced HIV-1-infected patients: a randomized open-label non-inferiortity trial, easier. In: Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada. February 8–11. 2009;Abstract 572
  21. Eron J, Andrade J, Zajdenverg R, Workman C, Cooper D, Young B, et al. Switching from stable lopinavir/ritonavir-based to raltegravir-based combination ART did not demonstrate non-inferior virologic efficacy at week 24. In: Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada. February 8–11. 2009;Abstract 70aLB
  22. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008;14:762–766
  23. Wilkin T, Ribaudo H, Gulick R. The relationship of CCR5 inhibitors to CD4 cell count changes: a meta-analysis of recent clinical trials in treatment-experienced patients. In: Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections. Boston, Massachussetts, February 3–6. 2008;Abstract 800
  24. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials. 2008;9:164–176
  25. Dornadula G, Chang H, VanUitert B, Stern J, Livornese L, Ingerman MJ, et al. Residual HIV-1 RNA in blood of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282:1627–1632
  26. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614–1622
  27. Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained RNA <200 copies/mL. J Infect Dis. 1998;177:235–238
  28. Finzi D, Hermankova , Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir of HIV-1 on highly active antiretroviral therapy. Science. 1997;278:1295–1300
  29. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125–133
  30. Zolopa A, Mullen M, Berger D, Ruane P, Hawkins T, Zhong L, et al. The HIV integrase inhibitor GS-9137 demonstrates potent ARV activity in treatment-experienced patients. In: Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, California. February 25–28. 2007;Abstract 143LB
  31. Jones J, McMahon D, Wiegand A, Kearney M, Palmer S, McNulty S, et al. No decrease in residual viremia during raltegravir intensification in patients on standard ART. In: Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada. February 8–11. 2009;Abstract 423b
  32. ClinicalTrials.gov; Available at www.clinicaltrials.gov/ct2/results?term=raltegravir. Accessed December 17, 2008.

PII: S1386-6532(09)00463-6

doi: 10.1016/j.jcv.2009.09.025

Journal of Clinical Virology
Volume 46, Issue 4 , Pages 305-308 , December 2009

Article Tools